What is a stock summary page? Click here for an overview.
Business Description
Enlivex Therapeutics Ltd
NAICS : 325412
SIC : 2834
ISIN : IL0011319527
Description
Enlivex Therapeutics Ltd is an Israel-based development-stage biopharmaceutical company. It is focused on developing and commercializing an allogeneic drug pipeline for rebalancing immune hyper-responses. The company's Allocetra is an immunotherapy that is being developed to rebalance a life-threatening unbalanced immune system, using the immune system's own natural regulation mechanisms.
Financial Strength
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 32.03 | |||||
| Equity-to-Asset | 0.89 | |||||
| Debt-to-Equity | 0.03 | |||||
| Debt-to-EBITDA | -0.05 | |||||
| Piotroski F-Score | 3/9 | |||||
| WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year EBITDA Growth Rate | -22 | |||||
| 3-Year EPS without NRI Growth Rate | -20.2 | |||||
| 3-Year FCF Growth Rate | -11.9 | |||||
| 3-Year Book Growth Rate | -12.7 | |||||
| Future 3-5Y EPS without NRI Growth Rate Estimate | 21.3 |
Momentum Rank
4/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 36.67 | |||||
| 9-Day RSI | 41.15 | |||||
| 14-Day RSI | 43.75 | |||||
| 3-1 Month Momentum % | 0.84 | |||||
| 6-1 Month Momentum % | -26.83 | |||||
| 12-1 Month Momentum % | -68.34 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 9.71 | |||||
| Quick Ratio | 9.71 | |||||
| Cash Ratio | 8.78 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -8.4 | |||||
| Shareholder Yield % | -6.6 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| ROE % | -62.75 | |||||
| ROA % | -53.63 | |||||
| ROIC % | -240.81 | |||||
| 3-Year ROIIC % | -684.15 | |||||
| ROC (Joel Greenblatt) % | -344.71 | |||||
| ROCE % | -51.46 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PB Ratio | 0.84 | |||||
| Price-to-Tangible-Book | 0.84 | |||||
| EV-to-EBIT | 0.08 | |||||
| EV-to-EBITDA | 0.08 | |||||
| EV-to-FCF | 0.09 | |||||
| Price-to-Net-Current-Asset-Value | 0.94 | |||||
| Price-to-Net-Cash | 1.05 | |||||
| Earnings Yield (Greenblatt) % | 1250 | |||||
| FCF Yield % | -63.65 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:ENLV
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Enlivex Therapeutics Ltd Executives
DetailsGF Value
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | |||
| EPS (TTM) ($) | -0.98 | ||
| Beta | 1.54 | ||
| 3-Year Sharpe Ratio | -0.43 | ||
| 3-Year Sortino Ratio | -0.58 | ||
| Volatility % | 76.46 | ||
| 14-Day RSI | 43.75 | ||
| 14-Day ATR ($) | 0.101175 | ||
| 20-Day SMA ($) | 1.10675 | ||
| 12-1 Month Momentum % | -68.34 | ||
| 52-Week Range ($) | 0.8101 - 4.59 | ||
| Shares Outstanding (Mil) | 21.99 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 3 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Enlivex Therapeutics Ltd Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Enlivex Therapeutics Ltd Stock Events
| Event | Date | Price ($) | ||
|---|---|---|---|---|
| No Event Data | ||||
Enlivex Therapeutics Ltd Frequently Asked Questions
What is Enlivex Therapeutics Ltd(ENLV)'s stock price today?
The current price of ENLV is $1.02. The 52 week high of ENLV is $4.59 and 52 week low is $0.81.
When is next earnings date of Enlivex Therapeutics Ltd(ENLV)?
The next earnings date of Enlivex Therapeutics Ltd(ENLV) is 2025-03-31 Est..
Does Enlivex Therapeutics Ltd(ENLV) pay dividends? If so, how much?
Enlivex Therapeutics Ltd(ENLV) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers